Published in J Urol on May 01, 2002
Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort. Am J Epidemiol (2009) 1.92
Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2014) 1.61
Associations between variants in the cyclooxygenase 2 enzyme gene (PTGS2) and development of benign prostate enlargement. BJU Int (2011) 1.41
The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine (2008) 1.41
CXCL5 promotes prostate cancer progression. Neoplasia (2008) 1.37
Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int J Cancer (2009) 1.29
Evaluation of prostatitis in autopsied prostates--is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol (2008) 1.28
Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol (2010) 1.11
Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J Transl Med (2012) 1.09
Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.03
Inflammatory Mechanisms Associated with Prostatic Inflammation and Lower Urinary Tract Symptoms. Curr Prostate Rep (2008) 1.02
Leukocytic promotion of prostate cellular proliferation. Prostate (2010) 0.98
Longitudinal association between prostatitis and development of benign prostatic hyperplasia. Urology (2008) 0.97
Upregulation of androgen-responsive genes and transforming growth factor-β1 cascade genes in a rat model of non-bacterial prostatic inflammation. Prostate (2013) 0.85
Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition. Oncogene (2016) 0.82
Progression of benign prostatic hyperplasia is associated with pro-inflammatory mediators and chronic activation of prostate-infiltrating lymphocytes. Oncotarget (2016) 0.81
Interleukin-17 Induces Expression of Chemokines and Cytokines in Prostatic Epithelial Cells but Does Not Stimulate Cell Growth In Vitro. Int J Med Biol Front (2012) 0.78
Influence of E. coli-induced prostatic inflammation on expression of androgen-responsive genes and transforming growth factor beta 1 cascade genes in rats. Prostate (2014) 0.78
Mucosa-associated lymphoid tissue lymphoma and concurrent adenocarcinoma of the prostate. Rare Tumors (2010) 0.78
Proliferative, structural and molecular features of the Mdx mouse prostate. Int J Exp Pathol (2010) 0.75
Prostate cancer incidence in men with self-reported prostatitis after 15 years of follow-up. Oncol Lett (2016) 0.75
Influence of chronic inflammation on Bcl-2 and PCNA expression in prostate needle biopsy specimens. Oncol Lett (2017) 0.75
A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts. Cancer Epidemiol Biomarkers Prev (2017) 0.75
The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc (2012) 3.45
Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer (2008) 3.14
Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation (2012) 2.78
Choices. J Urol (2006) 2.01
Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer (2007) 2.00
Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol (2002) 1.96
Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer (2004) 1.85
Benign intrascrotal lesions. J Urol (2004) 1.68
Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement. J Androl (2002) 1.66
Prognostic utility of erectile dysfunction for cardiovascular disease in younger men and those with diabetes. Am Heart J (2012) 1.65
Clear cell papillary renal cell carcinoma: a distinct histopathologic and molecular genetic entity. Am J Surg Pathol (2008) 1.64
Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas. Clin Cancer Res (2005) 1.63
Tubulocystic carcinoma of the kidney: clinicopathologic analysis of 31 cases of a distinctive rare subtype of renal cell carcinoma. Am J Surg Pathol (2009) 1.63
Evidence for common clonal origin of multifocal lung cancers. J Natl Cancer Inst (2009) 1.59
A novel computer based expert decision making model for prostate cancer disease management. J Urol (2005) 1.59
ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol (2011) 1.59
Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia (2004) 1.56
The NERI Hypogonadism Screener: psychometric validation in male patients and controls. Clin Endocrinol (Oxf) (2011) 1.53
Constitutive activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model. Prostate (2005) 1.48
Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer (2004) 1.45
The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. J Urol (2006) 1.45
Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res (2004) 1.45
Leiomyoma of the urethra and bladder. J Urol (2007) 1.44
Intestinal metaplasia of the bladder. J Urol (2006) 1.41
Prostatic stromal hyperplasia with atypia: follow-up study of 18 cases. Arch Pathol Lab Med (2008) 1.33
Bladder cancer: translating molecular genetic insights into clinical practice. Hum Pathol (2010) 1.33
Blockade of beta-catenin signaling by plant flavonoid apigenin suppresses prostate carcinogenesis in TRAMP mice. Cancer Res (2007) 1.32
The accuracy of the increased prostate specific antigen level (greater than or equal to 20 ng./ml.) in predicting prostate cancer: is biopsy always required? J Urol (2002) 1.31
Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH Registry. Urology (2009) 1.31
Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry. J Urol (2011) 1.25
Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. Hum Pathol (2009) 1.24
Residual and recurrent disease following renal energy ablative therapy: a multi-institutional study. J Urol (2006) 1.23
Inflammatory myofibroblastic tumors of the genitourinary tract--single entity or continuum? J Urol (2008) 1.22
Thyroid transcription factor 1 expression in small cell carcinoma of the urinary bladder: an immunohistochemical profile of 44 cases. Hum Pathol (2005) 1.21
Multilocular cystic renal cell carcinoma is a subtype of clear cell renal cell carcinoma. Mod Pathol (2010) 1.19
Does the size of the surgical margin in partial nephrectomy for renal cell cancer really matter? J Urol (2002) 1.19
Sonographic evaluation of penile trauma. J Ultrasound Med (2005) 1.19
Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res (2005) 1.19
Ureteral endometriosis: clinicopathological and immunohistochemical study of 7 cases. Hum Pathol (2008) 1.19
Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am J Pathol (2005) 1.19
Phase II clinical trial of interactive MR imaging-guided interstitial radiofrequency thermal ablation of primary kidney tumors: initial experience. Radiology (2004) 1.17
Tissue Harvester with Functional Valve (THFV): Shidham's device for reproducibly higher specimen yield by fine needle aspiration biopsy with easy to perform steps. BMC Clin Pathol (2007) 1.17
Differential expression of S100A2 and S100A4 during progression of human prostate adenocarcinoma. J Clin Oncol (2003) 1.15
Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era. J Urol (2004) 1.15
Large cell calcifying Sertoli cell tumor of testis. J Urol (2007) 1.13
Trials of new germ cell immunohistochemical stains in 93 extragonadal and metastatic germ cell tumors. Hum Pathol (2007) 1.13
Lymphoepithelioma-like carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, and molecular features. Am J Surg Pathol (2011) 1.11
Intraoperative cytology increases the diagnostic accuracy of frozen sections for the confirmation of various tissues in the parathyroid region. Am J Clin Pathol (2002) 1.09
Telomere shortening and chromosomal abnormalities in intestinal metaplasia of the urinary bladder. Clin Cancer Res (2007) 1.09
Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder. Clin Cancer Res (2007) 1.08
Histogenesis of clear cell adenocarcinoma in the urinary tract: evidence of urothelial origin. Clin Cancer Res (2008) 1.08
Molecular genetic alterations in the laser-capture-microdissected stroma adjacent to bladder carcinoma. Cancer (2003) 1.07
Soft tissue tumors of the urinary bladder Part II: malignant neoplasms. Hum Pathol (2007) 1.07
Sarcomatoid carcinoma of the upper urinary tract: clinical outcome and molecular characterization. Hum Pathol (2008) 1.05
Divergent pathway of intestinal metaplasia and cystitis glandularis of the urinary bladder. Mod Pathol (2006) 1.05
Male Sexual Health Questionnaire (MSHQ): scale development and psychometric validation. Urology (2004) 1.05
Urothelial carcinoma with an inverted growth pattern can be distinguished from inverted papilloma by fluorescence in situ hybridization, immunohistochemistry, and morphologic analysis. Am J Surg Pathol (2007) 1.05
TP53 mutational analysis supports monoclonal origin of biphasic sarcomatoid urothelial carcinoma (carcinosarcoma) of the urinary bladder. Mod Pathol (2008) 1.05
Development and validation of four-item version of Male Sexual Health Questionnaire to assess ejaculatory dysfunction. Urology (2007) 1.04
Molecular imaging of NF-kappaB in prostate tissue after systemic administration of IL-1 beta. Prostate (2008) 1.04
The impact of osteoporosis in men treated for prostate cancer. Urol Clin North Am (2004) 1.03
Xanthogranulomatous sialadenitis: a case report and literature review. Ear Nose Throat J (2005) 1.01
Up-regulation of insulin-like growth factor binding protein-3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice. FASEB J (2005) 1.00
Use of combination chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID). J Clin Immunol (2012) 1.00
Upregulation of SATB1 is associated with prostate cancer aggressiveness and disease progression. PLoS One (2013) 0.99
Primary testicular lymphoma. J Urol (2007) 0.99
Radiation cystitis. J Urol (2009) 0.98
Small cell carcinoma of the urinary bladder. Histol Histopathol (2010) 0.97
Laser-assisted microdissection in translational research: theory, technical considerations, and future applications. Appl Immunohistochem Mol Morphol (2013) 0.97
Diagnosis and treatment of erectile dysfunction for reduction of cardiovascular risk. J Urol (2013) 0.97
Prostatic leiomyoma with atypia: follow-up study of 10 cases. Ann Diagn Pathol (2008) 0.97
Association of tobacco use with hormone refractory disease and survival of patients with prostate cancer. J Urol (2004) 0.97
Adenomatoid tumor of the adrenal gland. J Urol (2008) 0.97
Immunohistochemical comparison of gastrointestinal stromal tumor and solitary fibrous tumor. Arch Pathol Lab Med (2002) 0.97
Phyllodes tumor of the prostate. J Urol (2005) 0.96
Priapism secondary to hypertriglyceridemia. J Urol (2003) 0.96
Squamous cell carcinoma of the renal pelvis. J Urol (2010) 0.96
Update on fused capromab pendetide imaging of prostate cancer. Clin Prostate Cancer (2005) 0.96
Evidence for polyclonal origin of multifocal clear cell renal cell carcinoma. Clin Cancer Res (2008) 0.95
Endometriosis of the ureter. J Urol (2008) 0.94
Mucinous tubular and spindle cell carcinoma of the kidney. J Urol (2009) 0.94
Sarcomatoid urothelial carcinoma of the renal pelvis. J Urol (2006) 0.94
Carcinoid tumor of the kidney. J Urol (2008) 0.94
Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: a fluorescence in situ hybridization and immunohistochemical analysis. Prostate (2008) 0.93
Il-1 beta-induced post-transition effect of NF-kappaB provides time-dependent wave of signals for initial phase of intrapostatic inflammation. Prostate (2009) 0.93
Apigenin attenuates insulin-like growth factor-I signaling in an autochthonous mouse prostate cancer model. Pharm Res (2011) 0.92
Soft tissue tumors of the penis: a review. Anal Quant Cytol Histol (2006) 0.92
Effects of testosterone replacement on response to sildenafil citrate. Ann Intern Med (2013) 0.92
c-kit Expression in small cell carcinoma of the urinary bladder: prognostic and therapeutic implications. Mod Pathol (2005) 0.92
Benign soft tissue tumors of the testis. J Urol (2009) 0.91
Sarcoidosis of the testis and epididymis. J Urol (2008) 0.91
Small cell carcinoma of the urinary bladder--histogenesis, genetics, diagnosis, biomarkers, treatment, and prognosis. Appl Immunohistochem Mol Morphol (2007) 0.91